The facility in Sudair Industrial City will manufacture instruments and assays to support local diagnostic testing and regional expansion.
Co-Diagnostics Inc announced that CoMira Diagnostics, the company’s joint venture with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia, has secured an industrial land allocation in Sudair Industrial City, Saudi Arabia. The approval, granted by the Saudi Authority for Industrial Cities and Technology Zones, allows for the development of a manufacturing facility dedicated to molecular diagnostic instruments and assays.
The final lease agreement is expected to be executed once site infrastructure requirements are completed. The facility is intended to localize diagnostic technologies within the region and support expansion across the Middle East and Northern Africa.
“We believe that a manufacturing facility in Sudair Industrial City could play an important role in achieving our JV’s mission to localize advanced diagnostic technologies within the KSA, including the Co-Dx PCR platform, and is expected to support our international expansion objectives across the Middle East and Northern Africa,” says Dwight Egan, CEO of Co-Diagnostics, in a release.
The project aligns with the Saudi Arabia Vision 2030 strategy, which aims to diversify the economy and strengthen domestic manufacturing. By producing diagnostics locally, the company expects to participate in government procurement programs where in-country manufacturing is a key differentiator.
“Securing our presence in Sudair Industrial City represents a foundational milestone for CoMira,” says Ihssan Rjoob, CEO of CoMira Diagnostics, in a release. “Once operational, the facility is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions, enabling faster access to innovative diagnostics while supporting national healthcare resilience.”
The planned facility will be designed to meet specific production and regulatory requirements for molecular diagnostic tools. The Co-Dx PCR platform, which includes the PCR Home, PCR Pro, and associated tests, is currently subject to review by the Food and Drug Administration and other regulatory bodies and is not yet available for sale.
ID 448726249 © M M | Dreamstime.com
